Yartemlea (narsoplimab-wuug) improves platelets hemolysis organ function hematopoietic stem cell transplant–associated thrombotic microangiopathy transplant patients
1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy, associated with improvements ...
![Engineered stem cells mitigate liver damage caused by radiation [PreClinical]](https://www.2minutemedicine.com/wp-content/uploads/2014/12/Human_embryonic_stem_cells-350x250.png)




